RBC Capital Markets increased its price target for Definium Therapeutics to $70, up from $66.

Nov 10, 2026, 8:03 AM ETOpinionRead the original at marketscreener.com

Good for DFTX

RBC raised its share-price estimate from $66 to $70 and kept its Outperform rating, supporting a more positive view. It still calls the shares speculative, so uncertainty remains.

DFTX · Definium Therapeutics, Inc.

AI read · Good for DFTX

The AI's read

The higher share-price estimate and continued Outperform rating show RBC sees more potential in Definium shares. The speculative-risk label warns that the shares still carry uncertainty. This is RBC's view, not proof that the company itself has improved.

Get alerts for DFTX

Follow Definium Therapeutics, Inc. (DFTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DFTX

Free on the App Store and Google Play, or on the web.